Becton, Dickinson and Company: stock overview

BDXNYSEHealthcare · Surgical & Medical Instruments & Apparatus

Price

$218.03

November 13, 2026Market cap $62.2B

What Ploutos Investor adds for Becton, Dickinson and Company

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from FY2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has risen 23% since Aug 6, 2026, when the 10-Q these figures come from was filed ($177.07 then, $218.03 on Nov 13, 2026). The figures date from before that move.10-Q
  • The latest annual figures the company filed are for 2025, more than a year ago. Newer ones may be late.

In short

Becton, Dickinson and Company had revenue of $22.4B over the last 12 months and net income of $941M, a net margin of 4.2%. Revenue grew by 6.3% a year on average over the last 5 years. At $218.03 the shares trade at a P/E of 66.1, against a median of 37.9 over the last 5 fiscal years. It has net debt of $16.1B. It pays a dividend yielding 1.82%.

From its SEC filings (latest fiscal year to September 30, 2025) and the price of November 13, 2026.

Its SEC filings
Market cap
$62.2B
285M shares
P/E
66.1
Today66.1
Median37.9
Revenue, 12 months
$22.4B
+6.3% a year over 5 years
Net margin
4.2%
FY2025: 7.7%, above 64% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

FY2023–FY2025 fiscal years

+6.2% a year over 2 years

  • FY2025Sep 30, 202510-K
    Revenue$21.8B
  • FY2024Sep 30, 202410-K
    Revenue$20.2B
  • FY2023Sep 30, 202310-K
    Revenue$19.4B

Fiscal years in figures

BDX's revenue, profit, cash flow and dividend with each year-end price, from FY2009 to FY2022, 14 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $69.7B
$62.2B
Enterprise value 
$78.3B
P/E 3-year median: 41.1
66.1
EV / EBIT 
33.9
EV / Revenue 
3.5
P/B 3-year median: 2.7
2.6
FCF yield 3-year median: 4.5%
5.1%
Earnings yield 3-year median: 2.4%
1.5%

Profitability

Gross margin 
46.7%
Operating margin 
10.3%
Net margin 3-year median: 7.7%
4.2%
ROIC 
4.7%
ROIC, 5-year average 
4.3%
ROE 
3.8%

Growth

Revenue, yearly change 
+8.2%
EPS, yearly change 
-0.7%
FCF, yearly change 
-14.4%
Revenue, average a year 
+6.3%
EPS, average a year 
+16.5%

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash 
$709M
Total debt 
$16.8B
Net debt 
$16.1B
Net debt / EBITDA 
3.4x
Interest cover 
3.9x
Current ratio 
0.87

Balance sheet of June 30, 2026.

Returns to shareholders

Dividend yield 3-year median: 1.6%
1.82%
Buybacks 
1.61%
Total returned 
3.43%
Shares, yearly change 
-1.3%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 38).

Operating margin

11.8%

Above 66% of the 186 companies in its industry, and 68% of all.

Net margin

7.7%

Above 64% of the 189 companies in its industry, and 60% of all.

ROE

6.6%

Above 61% of the 174 companies in its industry, and 48% of all.

ROA

3.1%

Above 60% of the 190 companies in its industry, and 61% of all.

Revenue growth

8.2%

Above 52% of the 186 companies in its industry, and 57% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
BECTON DICKINSON & CO
Exchange
NYSE
Industry (SIC)
3841 · Surgical & Medical Instruments & Apparatus
Fiscal year ends
September 30
Latest annual report
September 30, 2025
Reporting currency
USD
Shares
285M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do Becton, Dickinson and Company's filings show?

These are Becton, Dickinson and Company's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about BDX

Didn't find what you were looking for?

Ask us
What is BDX's market cap?

Becton, Dickinson and Company's market cap is $62.2B, at a price of $218.03 on November 13, 2026 and 285M shares.

What is BDX's P/E?

BDX's P/E is 66.1, on earnings per share of $3.32 over the last 12 months. The median over the last 5 fiscal years was 37.9.

How much revenue does BDX have?

Becton, Dickinson and Company had revenue of $22.4B over the last 12 months. Over the last 5 years it changed by +6.3% a year on average.

Does BDX pay a dividend?

Yes. Becton, Dickinson and Company paid $3.98 per share over the last 12 months, a yield of 1.82% at today's price. All the figures are in the Dividend section.

Where do the figures come from?

From Becton, Dickinson and Company's SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.